A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae

► We produced MS2 VLPs which packaging HIV-1 gag mRNA in Saccharomyces cerevisiae. ► The RNA contents of MS2 VLPs are protected from degradation by the capsid protein. ► MS2 VLP-mediated mRNA vaccine induced antigen-specific antibody responses in mice.